Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors
Yasutoshi Kuboki(National Cancer Center Hospital East), Noboru Yamamoto(Tokyo National Hospital), J. luke Jason(University of Chicago), Apurvasena Parikh(AbbVie (United States)), Greg Vosganian(AbbVie (United States)), Stefan Englert(AbbVie (Germany)), Rasco Drew(Houston Methodist), Eisuke Shimizu(Keio University), Lambert Stacie(AbbVie (United States)), Shunsuke Kondo(University of Hawaiʻi at Mānoa), Spira Alexander(Virginia Cancer Specialists), Powderly John(Carolina BioOncology Institute), Toshihiko Doi(National Cancer Center Hospital East), Hideyuki Hashiba(ABB (Japan)), Afar Daniel(AbbVie (United States))
Cited by 1
Related Papers
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
|The Lancet. Gastroenterology & hepatology|2019|331